ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

摘要:

The market for hormone replacement therapy (HRT) products is vast and largely untapped. Two new concepts in HRT, recently launched in the UK, are hoped to realise that market by giving women easier, more palatable options for therapy. There are also plenty more ideas in the pipeline. One of the recently launched products is ‘Tridestra’. It is the first HRT product to be taken in 91-day cycles, resulting in 4 periods of withdrawal bleeding per year, rather than 13. It is licensed for the treatment of menopausal symptoms in peri- and postmenopausal women, and the prevention of postmenopausal osteoporosis.

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

摘要:

Routine substitution of alteplase for streptokinase for treating acute myocardial infarction (MI) is cost effective, according to Dr Daniel Mark and fellow investigators involved with the GUSTO* trial.1Their analysis suggests that the incremental cost-effectiveness value of alteplase is $US32 678/life-year saved. Putting this into context, using alteplase to treat the approximately 250 000 eligible patients in the US who present with acute MI each year would cost around $US500 million annually, but would yield 3.5 million additional years of life for alteplase recipients.

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS